Fulgent Genetics, Inc. operates primarily as a clinical laboratory services company, providing comprehensive diagnostic and genetic testing solutions to physicians, hospitals, and healthcare providers. The company's core laboratory services segment generates the vast majority of its revenue and encompasses molecular diagnostic testing, anatomic pathology, and oncology testing. Its proprietary technology platform integrates gene probes, data suppression algorithms, and laboratory information management systems to deliver flexible sequencing services. Through its clinical laboratories, Fulgent analyzes various biological samples to identify genetic markers associated with hereditary cancers, reproductive health issues, and infectious diseases.
In addition to its established diagnostics business, Fulgent has expanded into therapeutic development following its acquisition of Fulgent Pharma. This segment focuses on discovering and developing drug candidates for oncology, utilizing a nanoencapsulation and targeted therapy platform designed to improve the pharmacokinetic profile of cancer drugs. Although the therapeutic division is currently in the clinical trial stage and does not yet generate significant commercial revenue, it represents a strategic shift toward becoming a fully integrated precision medicine company. Geographically, the company is headquartered in El Monte, California, and serves a diverse client base across the United States and internationally, including medical institutions, insurance payors, and governmental bodies.
